Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novo Nordisk is currently navigating a period of mixed clinical results across its pipeline, marked by both significant breakthroughs and strategic retreats. Recent reports indicate that the company has scrapped two additional Phase 3 trials for its heart drug, ziltivekimab, which has resulted in diminishing expectations for the company's growth beyond its established obesity treatments. Simultaneously, the company has reported a major win in its pediatric obesity program, where a Phase 3 trial for a child obesity drug successfully met its primary endpoint, signaling a potential new growth avenue. Coverage from multiple industry outlets emphasizes the stark contrast between these outcomes. Fierce Pharma reports that Wegovy helped 40% of children achieve freedom from obesity during the Phase 3 trial.
This success is echoed by Barron's, which notes that GLP-1 drugs are effective for children and could represent another massive market for the company. Conversely, Clinical Trials Arena focuses on the failures of ziltivekimab, describing the termination of the pair of Phase 3 trials as another stumble for the drug. The Economic Times (Pharma) underscores that these scrapped heart drug trials dim the prospects for diversification away from the obesity sector, which has been the primary driver of the company's recent success. To understand why these events are significant, one must consider Novo Nordisk's reliance on its obesity portfolio. The market is closely monitoring whether the company can successfully pivot from a primary focus on weight loss to a broader cardiovascular and renal health provider.
The contrast between the Wegovy results and the ziltivekimab terminations illustrates the high-risk, high-reward nature of late-stage clinical development in the pharmaceutical industry. Looking forward, observers will monitor how Novo Nordisk integrates the pediatric obesity findings into its commercial strategy and regulatory filings. According to the reports from MarketScreener and other outlets, the meeting of the primary endpoint in the child obesity drug trial provides a concrete path toward a new patient demographic. Meanwhile, the termination of the ziltivekimab trials suggests a pivot or a reduction in investment regarding those specific heart drug applications. Future updates will likely focus on the specific regulatory timelines for the pediatric drug and any remaining clinical paths for the company's cardiovascular pipeline.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 66d ago.
Quick answers
What happened to Novo Nordisk's ziltivekimab trials?
Novo Nordisk scrapped two more Phase 3 trials for ziltivekimab, which are described as further stumbles for the heart drug.
What were the results of the pediatric obesity trial?
The Phase 3 trial met its primary endpoint, and Fierce Pharma reports that Wegovy helped 40% of children become free from obesity.
Which drug class is showing promise for children according to Barron's?
Barron's reports that GLP-1 drugs work for kids and could represent another huge market for Novo Nordisk.
Coverage (5)
- Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug marketscreener.com · 69d ago
- Novo scraps two more heart drug trials, further dimming growth beyond obesity pharma.economictimes.indiatimes.com · 69d ago
- GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could Be Another Huge Market. Barron's · 69d ago
- Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial Fierce Pharma · 69d ago
- Novo Nordisk’s ziltivekimab stumbles again on pair of Phase III terminations Clinical Trials Arena · 69d ago
Topics
Related trends
Hundreds of children in England prescribed weight-loss jabs, figures show
Recent figures reveal hundreds of children in England are receiving GLP-1 weight-loss prescriptions.
Makers of obesity drugs hit back at claims of negative side effects
Makers of blockbuster weight loss drugs defend product safety amid mounting scrutiny over potential side effects.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.